All In Biotech

Drug Trial Radar · NCT07773727

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

Oct 29, 2029

Study completion Feb 18, 2030

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Interventions

  • ARGX-121Biological

    Subcutaneous Injection of ARGX-121

  • PlaceboBiological

    Subcutaneous Injection of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in proteinuria from baseline to week 24 as measured by the log-transformed urine protein-to-creatinine ratio (UPCR) derived from 24-h urine collection.Time frame: Up to 24 weeks

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Amicis Research Center - Valencia

    Valencia, California · Recruiting

  • Bioresearch Partners

    Miami, Florida · Recruiting

  • Nephrology Associates of South Miami PA

    Miami, Florida · Recruiting

  • BioResearch Partner - Pembroke Pines

    Pembroke Pines, Florida · Recruiting

  • Michigan Kidney Consultants

    Pontiac, Michigan · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Recruiting

  • Northwest Houston Arthritis Center - Houston

    Houston, Texas · Not yet recruiting

  • Utah Kidney Research Institute

    Salt Lake City, Utah · Recruiting

  • Kidney and Hypertension Specialists- Virginia

    Manassas, Virginia · Recruiting

  • Japanese Red Cross Fukuoka Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

  • Sapporo City General Hospital

    Sapporo, Hokkaidô, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.